Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Rahul S. Vedula, Hannah Q. Karp, Jeremy Koob, Felicia Lim, Jacqueline S. Garcia, Eric S. Winer, Marlise R. Luskin, Gabriel Ghiaur, Annette S. Kim, Lan W. Beppu, Olga Sala-Torra, Jerald Radich, Jonathan Gootenberg, Omar Abudayyeh, Feng Zhang, R. Coleman Lindsley

Blood (2024) 144 (12): 1290–1299.

https://doi.org/10.1182/blood.2023022908

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 9647–9649.

https://doi.org/10.1182/blood-2022-164444

Published: 2022

Journal Articles

New approaches to molecular monitoring in CML (and other diseases)

Jerald Radich, Cecilia Yeung, David Wu

Blood (2019) 134 (19): 1578–1584.

https://doi.org/10.1182/blood.2019000838

Published: 2019

Journal Articles

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Jorge E. Cortes, MD, Qian Jiang, MD, Jianxiang Wang, MD, Jianyu Weng, MD, Huanling Zhu, MD, Liu Xiaoli, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Jerald Radich, MD, Michael R. Savona, MD, Patricia Martin Regueira, MD, Oumar Sy, PhD, Renuka Gurnani, BA, Giuseppe Saglio

Blood (2018) 132 (Supplement 1): 788.

https://doi.org/10.1182/blood-2018-99-111978

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Thomas Delea, MBA, MSIA, Nicholas Despiegel, Diana Boyko, Jordan Amdahl, Ze Cong, PhD MS, Jerald Radich, MD

Blood (2018) 132 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2018-99-115230

Published: 2018

Journal Articles

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Zhaohui Gu, PhD, Michelle L. Churchman, PhD, Kathryn G. Roberts, PhD, Ian Moore, MS, Xin Zhou, PhD, Joy Nakitandwe, PhD, Kohei Hagiwara, MD, Stephane Pelletier, PhD, Sebastian Gingras, PhD, Hartmut Berns, PhD, Debbie Payne-Turner, Ashley Hill, BS, Ilaria Iacobucci, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Cheng Cheng, PhD, Deqing Pei, MS, Chunxu Qu, PhD, Meenakshi Devidas, PhD, Yunfeng Dai, PhD, Shalini C. Reshmi, PhD, Julie Gastier Foster, PhD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent Wood, MD PhD, William L. Carroll, MD, Patrick Zweider McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly W. Maloney, MD, Alessandro Rambaldi, MD PhD, Orietta Spinelli, PhD, Jerald Radich, MD, Mark D. Minden, MD PhD, Jacob M. Rowe, MD, Selina Luger, MD, Mark R. Litzow, MD, Martin S. Tallman, MD, Janis Recevskis, PhD, Yanming Zhang, Ravi Bhatia, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Clara D. Bloomfield, MD, Wendy Stock, MD, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD, Marina Y. Konopleva, MD PhD, William E. Evans, PharmD, Sima Jeha, MD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Elisabeth M. Paietta, PhD, James R. Downing, MD, Mary V Relling, PharmD, Jinghui Zhang, Mignon L. Loh, MD, Stephen P. Hunger, MD, Charles G. Mullighan, MBBS, MD

Blood (2018) 132 (Supplement 1): 565.

https://doi.org/10.1182/blood-2018-99-111219

Published: 2018

Journal Articles

Understanding CML, 1 cell at a time

Jerald Radich

Blood (2017) 129 (17): 2339–2340.

https://doi.org/10.1182/blood-2017-02-765578

Published: 2017

Journal Articles

The effect of long-term ruxolitinib treatment on JAK2 p.V617F allele burden in patients with myelofibrosis

Michael Deininger, Jerald Radich, Timothy C. Burn, Reid Huber, Dilan Paranagama, Srdan Verstovsek

Blood (2015) 126 (13): 1551–1554.

https://doi.org/10.1182/blood-2015-03-635235

Published: 2015

Includes: Supplemental data

Journal Articles

Splicing up the classification of myelodysplasia

Jerald Radich

Blood (2015) 126 (2): 128–129.

https://doi.org/10.1182/blood-2015-05-645713

Published: 2015

Journal Articles

BCR-ABL Testing Frequency Lower Than NCCN Recommendations in Lab Network Review of CML Patients

Carol Smyth, MB, Jason Bhan, MD, Tatiana Sorokina, MSc, Niyati Parikh, MSc, Vivian Oehler, MD, Jerald Radich, MD

Blood (2014) 124 (21): 1807.

https://doi.org/10.1182/blood.V124.21.1807.1807

Published: 2014

Journal Articles

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Fabiana Ostronoff, Megan Othus, Robert B. Gerbing, Michael R. Loken, Susana C. Raimondi, Betsy A. Hirsch, Beverly J. Lange, Stephen Petersdorf, Jerald Radich, Frederick R. Appelbaum, Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi

Blood (2014) 124 (15): 2400–2407.

https://doi.org/10.1182/blood-2014-04-570929

Published: 2014

Includes: Supplemental data

Journal Articles

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Michael Mauro, MD, Jerald Radich, MD, Jorge E. Cortes, MD, Shaker Dakhil, MD, Christopher Keir, MD, Sandy Yi, Martha Wadleigh, MD, Vivian G. Oehler, MD, Thomas Ervin, MD, Stuart Goldberg, MD, Michael Savona, MD, FACP

Blood (2013) 122 (21): 4015.

https://doi.org/10.1182/blood.V122.21.4015.4015

Published: 2013

Journal Articles

Patients With Philadelphia-Positive Leukemia With BCR-ABL Kinase Mutations Prior To Allogeneic Transplantation Predominantly Relapse With The Same Mutation

Daniel N. Egan, MD, Lan Beppu, Jerald Radich, MD

Blood (2013) 122 (21): 4043.

https://doi.org/10.1182/blood.V122.21.4043.4043

Published: 2013

Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2013) 122 (21): 1315.

https://doi.org/10.1182/blood.V122.21.1315.1315

Published: 2013

Journal Articles

NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG

Fabiana Ostronoff, MD, Megan Othus, PhD, Robert B. Gerbing, MA, Michael R. Loken, PhD, Susana C Raimondi, PhD, Betsy A. Hirsch, PhD, Beverly J. Lange, MD, Stephen Petersdorf, MD, Jerald Radich, MD, Frederick R. Appelbaum, MD, Alan S. Gamis, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 488.

https://doi.org/10.1182/blood.V122.21.488.488

Published: 2013

Journal Articles

Altered Hematopoietic Cell Gene Expression Identifies Patients at Risk for Development of Therapy-Related Leukemia (t-MDS/AML)

Liang Li, Min Li, Can-Lan Sun, Liton Francisco, Melanie Sabado, Tinisha McDonald, Janelle Gyorffy, Karen Chang, Shirong Wang, Wenhong Fan, Jiangning Li, Lue Ping Zhao, Jerald Radich, Stephen J. Forman, Smita Bhatia, Ravi Bhatia

Blood (2010) 116 (21): 234.

https://doi.org/10.1182/blood.V116.21.234.234

Published: 2010

Journal Articles

Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia.

Dong Hwan (Dennis) Kim, Jung A. Kim, Jina Yun, Lakshmi Sriharsha, Jun Ho Jang, Kihyun Kim, Chul Won Jung, Suzanne Kamel-Reid, Jerald Radich, Jeffrey H. Lipton

Blood (2009) 114 (22): 1110.

https://doi.org/10.1182/blood.V114.22.1110.1110

Published: 2009

Journal Articles

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

Blood (2009) 114 (22): 2212.

https://doi.org/10.1182/blood.V114.22.2212.2212

Published: 2009

Journal Articles

Gene Expression Changes in CD34+ Cells Precede Development of Therapy-Related Leukemia (t-MDS/AML) After Autologous Hematopoietic Cell Transplantation (aHCT) for Hodgkin (HL) or Non-Hodgkin Lymphoma (NHL).

Liang Li, Min Li, Can-Lan Sun, Melanie D. Sabado, Liton Francisco, Tinisha McDonald, Karen L. Chang, Shirong Wang, Jerald Radich, Lue Ping Zhao, Stephen J. Forman, Smita Bhatia, Ravi Bhatia

Blood (2009) 114 (22): 677.

https://doi.org/10.1182/blood.V114.22.677.677

Published: 2009

NARROW

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

New approaches to molecular monitoring in CML (and other diseases)

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Cost-Effectiveness of Blinatumomab Versus Standard of Care in Adult Patients with Philadelphia-Chromosome-Negative B-Precursor Acute Lymphoblastic Leukemia in First Hematological Complete Remission (CR) with Minimal Residual Disease (MRD) from a US Payer Perspective

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Understanding CML, 1 cell at a time

The effect of long-term ruxolitinib treatment on JAK2 p.V617F allele burden in patients with myelofibrosis

Splicing up the classification of myelodysplasia

BCR-ABL Testing Frequency Lower Than NCCN Recommendations in Lab Network Review of CML Patients

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Patients With Philadelphia-Positive Leukemia With BCR-ABL Kinase Mutations Prior To Allogeneic Transplantation Predominantly Relapse With The Same Mutation

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG

Altered Hematopoietic Cell Gene Expression Identifies Patients at Risk for Development of Therapy-Related Leukemia (t-MDS/AML)

Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia.

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

Gene Expression Changes in CD34+ Cells Precede Development of Therapy-Related Leukemia (t-MDS/AML) After Autologous Hematopoietic Cell Transplantation (aHCT) for Hodgkin (HL) or Non-Hodgkin Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only